Related references
Note: Only part of the references are listed.To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma
Bharathan Bhavya et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2020)
Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness
Vivek Tiwari et al.
NEURO-ONCOLOGY (2020)
Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019
Markus J. Riemenschneider et al.
CLINICAL NEUROPATHOLOGY (2020)
Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile
Francesca Branzoli et al.
CURRENT OPINION IN NEUROLOGY (2020)
Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis
Chong Hyun Suh et al.
EUROPEAN RADIOLOGY (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency
Satsuki Miyata et al.
SCIENTIFIC REPORTS (2019)
Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET
Franziska Vettermann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas
Hao Zhou et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with H-1-MRS
Katharina J. Wenger et al.
NMR IN BIOMEDICINE (2019)
A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy
Xin Shen et al.
METABOLITES (2019)
Static and dynamic F-18-FET PET for the characterization of gliomas defined by IDH and 1p/19q status
Antoine Verger et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma
Hiroaki Nagashima et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data
Chong Hyun Suh et al.
NEURO-ONCOLOGY (2018)
A comparison of 2-hydroxyglutarate detection at 3 and 7T with long-TE semi-LASER
Adam Berrington et al.
NMR IN BIOMEDICINE (2018)
cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2018)
Predicting IDH genotype in gliomas using FET PET radiomics
Philipp Lohmann et al.
SCIENTIFIC REPORTS (2018)
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
Llewellyn E. Jalbert et al.
SCIENTIFIC REPORTS (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla
Gaurav Verma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma
Hiroaki Nagashima et al.
NEURO-ONCOLOGY (2016)
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study
Eike Steidl et al.
PLOS ONE (2016)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Elisabet Cuyas et al.
ONCOTARGET (2015)
IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
Alexandra R. Grassian et al.
CANCER RESEARCH (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma
Li Chen et al.
NEURO-ONCOLOGY (2014)
Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase
Jose L. Izquierdo-Garcia et al.
PLOS ONE (2014)
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Fumiharu Ohka et al.
TUMOR BIOLOGY (2014)
A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Adnan Elhammali et al.
CANCER DISCOVERY (2014)
Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach
Markus J. Riemenschneider et al.
ACTA NEUROPATHOLOGICA (2013)
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Ovidiu C. Andronesi et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
Whitney B. Pope et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas
Changho Choi et al.
NATURE MEDICINE (2012)
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
Ovidiu C. Andronesi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
PET and SPECT Studies of Brian Tumors with Radiolabeled Amino Acids
K. -J Langen et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package
D. Stefan et al.
MEASUREMENT SCIENCE AND TECHNOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Urinary Metabolite Quantification Employing 2D NMR Spectroscopy
Wolfram Gronwald et al.
ANALYTICAL CHEMISTRY (2008)
Bias in error estimation when using cross-validation for model selection
S Varma et al.
BMC BIOINFORMATICS (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
